High dose rate endobronchial brachytherapy in combination with external beam radiotherapy for stage III non-small cell lung cancer

Abstract

Introduction: A phase-II study was planned to test the effect of external beam radiotherapy in combination with endobronchial brachytherapy on the local control and survival of stage-III non-small cell lung cancer patients. Materials and methods: Thirty patients with stage-III non-small cell lung cancer have been treated with 60 Gy external beam radiotherapy and 3×5 Gy HDR endobronchial brachytherapy to control tumor and to prolong survival. Results: Therapy regimen was found to be very effective for the palliation of major symptoms, palliation rates were 42.8% for cough, 95.2% for hemoptysis, 88.2% for chest pain and 80.0% for dyspnea. There was a 76.7% tumor response (53.3% complete, 23.3% partial) verified by chest CT scans and bronchoscopy. However, median locoregional disease free survival was 9±4 months (95% CI: 1–17) and it was only 9.6% at 5 years. Major side effects were radiation bronchitis (70.0%), esophagitis (6.6%) in the acute period and bronchial fibrosis (25%), esophagial fibrosis (12.5%) and fatal hemoptysis (10.5%) in the late period. Median survival was 11±4 months (95% CI: 4–18),and 5-year actuarial survival was 10%. Locoregional disease free survival ( P=0.008) and the overall survival was longer ( P<0.001) in the patients younger than 60, survival was also improved in the patients with complete response ( P=0.019). There were no major complications during catheterisation; early side effects were quite tolerable but severe late complications were around 10%. Conclusions: It is concluded that endobronchial brachytherapy in combination with external irradiation provides a good rate of response, however does not eradicate locoregional disease and does not prolong survival except for some subgroups such as younger patients.